Last reviewed · How we verify
Alocril (NEDOCROMIL)
Alocril (Nedocromil) is a small molecule mast cell stabilizer that targets G-protein coupled receptor 35. Originally developed by King Pharma, it was acquired by Allergan and approved by the FDA in 1992 for the treatment of allergic conjunctivitis, asthma, and ocular itching. As an off-patent medication, it is available as a generic. Key safety considerations include its short half-life of 0.9 hours and low bioavailability of 3%. Alocril is used to prevent the release of histamine and other mediators from mast cells, reducing inflammation and symptoms associated with allergic reactions.
At a glance
| Generic name | NEDOCROMIL |
|---|---|
| Sponsor | AbbVie |
| Drug class | Mast Cell Stabilizer |
| Target | G-protein coupled receptor 35 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1992 |
Approved indications
- Allergic conjunctivitis
- Asthma
- Asthma management
- Ocular Itching
Common side effects
- headache
Key clinical trials
- Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232) (PHASE3)
- Immune Dysregulation in Children and Adults With Asthma (NA)
- Early Airway Response to Allergen in Asthmatics (MK-0000-176) (PHASE1)
- Comparing Modified Meek and Mesh Techniques (NA)
- Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |